MEDVi, Ivim Health and the operator of SkinnyRx were among those cited on 20 February 2026 over labelling and marketing claims.
FDA issued warning letters dated 20 February 2026 to several telehealth companies marketing compounded GLP-1 medicines, citing misbranding — labelling and marketing that blurred the line between a compounded preparation and an FDA-approved product, and in at least one case implying the telehealth company was itself the compounding pharmacy when it coordinates care rather than dispensing.
A warning letter is not a finding of patient harm and it is not a ban. It is a formal statement that the agency considers specific claims unlawful, and it creates a public record you can search by company name before enrolling anywhere.
We record warning letters on the affected provider pages as reported, and state plainly that we have not independently verified them. The programmes involved continue to operate, and their inclusion in our tables is unchanged — the letters concern how the products were described, not whether they were delivered.
The practical lesson for a patient is narrower than the headlines suggest: read what a programme claims about FDA status. If a page implies a compounded preparation is approved, equivalent or FDA-reviewed, that claim is the thing regulators are acting on.
Sources
- FDA warning letters, 20 February 2026, as reported by named provider reviews
- FDA human drug compounding programme — source
Dated 2026-02-20. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.